Icodextrin provides long dwell peritoneal dialysis and maintenance of intraperitoneal volume

Artificial Organs

Volumn 22, Issue 1, 1998, Pages 8-12

  Peers, Elizabeth ^a   Gokal, Ram ^b  

^a Blaby Hall   (United Kingdom)

^b NONE

Author keywords

Glucose polymer; Icodextrin; Intraperitoneal vehicle; Peritoneal dialysis

Indexed keywords

CONTROLLED DRUG DELIVERY; DIALYSIS; TARGETED DRUG DELIVERY; ULTRAFILTRATION;

ANTICANCER DRUG; CLINICAL EXPERIENCE; DAILY USE; DRUG-DELIVERY SYSTEMS; GLUCOSE POLYMER; ICODEXTRIN; INTRAPERITONEAL; INTRAPERITONEAL VEHICLE; PERITONEAL DIALYSIS; RENAL FAILURE;

GLUCOSE;

ANTIRETROVIRUS AGENT; DRUG VEHICLE; EXTRANEAL; FLUOROURACIL; GLUCOSE POLYMER; ICODEXTRIN; UNCLASSIFIED DRUG;

CARCINOMATOUS PERITONITIS; CLINICAL TRIAL; CONFERENCE PAPER; CONTINUOUS AMBULATORY PERITONEAL DIALYSIS; DRUG ABSORPTION; DRUG DELIVERY SYSTEM; DRUG EFFICACY; DRUG METABOLISM; DRUG TOLERABILITY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; INTRAPERITONEAL DRUG ADMINISTRATION; KIDNEY FAILURE; PRIORITY JOURNAL; ULTRAFILTRATION;

HUMAN IMMUNODEFICIENCY VIRUS;

EID: 0031914771     PISSN: 0160564X     EISSN: None     Source Type: Journal    
DOI: 10.1046/j.1525-1594.1998.06055.x     Document Type: Conference Paper

References (24)

1. Dobbie JW. New concepts in molecular biology and ultrastructural pathology of the peritoneum: Their significance for peritoneal dialysis. Am J Kidney Dis 1990;15:97-109.
2. DiZerega G. Use of adhesion prevention barriers in pelvic reconstructive and gynaecologic surgery. In: Pelvic surgery: Adhesion formation and prevention. New York: Springer, 1997:188-209.
3. Winchester JF, Stegink LD, Ahmad S, Gross M, Hammeke M, Horowitz AM, Maher JF, Pollak V, Rakowski T, Schreiber M, Singh S, Somani P, Vidt D. A comparison of glucose polymers and dextrose as osmotic agents in CAPD. In: Maher JF, Winchester JF, eds. Frontiers in peritoneal dialysis. (Proceedings IIIrd International Symposium on Peritoneal Dialysis). New York: Field and Rich, 1986:231-40.
4. Mistry CD, Gokal R. Can ultrafiltration occur with a hypoosmolar solution in peritoneal dialysis? The role for "colloid" osmosis. Clin Sci 1993;85:495-500.
5. de Fijter CWH, Verbrugh HA, Oe PL, Heezius E, Donker AJM, Verhoef J, Gokal R. Biocompatibility of a glucose-polymer containing peritoneal dialysis fluid. Am J Kidney Dis 1993;21:411-8.
6. Thomas S, Schenk U, Fischer FP, Mettang T, Passlick-Deetjen J, Kuhlmann U. In vitro effects of glucose-polymer containing peritoneal dialysis fluids on phagocytic activity. Am J Kidney Dis 1997;29:246-53.
7. Mistry CD, Gokal R, Peers EM. A randomized multicenter clinical trial comparing isosmolar icodextrin with hyperosmolar glucose solution in continuous ambulatory peritoneal dialysis: A six month study. Kidney Int 1994;46:496-503.
8. Posthuma N, ter Wee PM, Verbrugh HA, Oe PL, Peers E, Sayers J, Donker AJM, et al. Icodextrin instead of glucose during the daytime dwell in CCPD increases ultrafiltration and 24-h dialysate creatinine clearances. Nephrol Dial Transplant 1997;12:550-3.
9. Ota K, Mineshima M, Watanabe N, Naganuma S. Functional deterioration of the peritoneum: Does it occur in the absence of peritonitis? Nephrol Dial Transplant 1987;2:30-3.
10. Mistry CD, Mallick NP, Gokal R. Ultrafiltration with an isosmotic solution during long peritoneal dialysis exchanges. Lancet 1987;2:178-82.
11. Davies DS. Kinetics of icodextrin. Perit Dial Int 1994;14 (Suppl. 2):S45-50.
12. Lundquist A, Ockerman PA, Schersterin B. Fine needle aspiration biopsy of the liver in healthy adults: Activity of enzyme of glycogen utilisation and glucose production. Enzymol Biol Clin 1989;10:8.
13. Hers AG. α-Glucosidase deficiency in generalised glycogen storage disease. Biochem J 1963;86:11.
14. Mistry CD, Gokal R. Single daily overnight (12-hr dwell) use of 7.5% glucose polymer (Mw 18,700; Mn 7,300) + 0.35% glucose solution: A 3-month study. Nephrol Dial Transplant 1993;8:443-7.
15. Gokal R, Mistry CD, Peers EM, the MIDAS study group. Peritonitis occurrence in a multicentre study of icodextrin and glucose in CAPD. Perit Dial Int 1995;15:226-30.
16. Millar DJ, Dawnay A. Glycation and advanced glycation end-product formation with icodextrin and dextrose. Perit Dial Int 1997;17:52-8.
17. Stein A, Peers EM, Hattersley J, Harris K, Feehally J, Walls J, the MIDAS study group. Clinical experience with icodextrin in continuous ambulatory peritoneal dialysis patients. Perit Dial Int 1994;14 (Suppl. 2):S51-4.
18. Peers EM, Scrimgeour AC, Haycox AR. Cost-containment in CAPD patients with ultrafiltration failure. Clin Drug Invest 1995;10:53-8.
19. Diaz-Buxo JA, Farmer CD, Chandler CT, Walker P, Burgess WP. CCPD: Wet is better than dry. Perit Dial Bull 1987;7 (Suppl):S22.
20. Cooper A, Henderson IS, Jones MC. Daytime dwell with 7.5% icodextrin in automated peritoneal dialysis (APD). J EDTNA-ERA 1995;21 (Suppl. 1):21.
21. Posthuma N, ter Wee PM, Donker AJM, Oe PL, Verbrugh HA, Peers E. Disaccharide (total maltose) levels in CCPD patients using icodextrin. J Am Soc Nephrol 1995;6:513.
22. McArdle CS, Kerr DJ, O'Gorman P, Wotherspoon HA, Warren H, Watson D, Vinké BJ, Dobbie JW, El Eini DID. Pharmacokinetic study of 5-fluorouracil in a novel dialysate solution: A long term intraperitoneal treatment approach for advanced colorectal carcinoma. Brit J Cancer 1994;70:762-6.
23. Kerr DJ, Young AM, Neoptolemos JP, Sherman M, Van-Geene P, Stanley A, Ferry D, Dobbie JW, Vincke B, Gilbert J, El Eini D, Dombros N, Fountzilas G. Prolonged intraperitoneal infusion of 5-fluorouracil using a novel carrier solution. Brit J Cancer 1996;74:2032-5.
24. Pantaleo G, Graziosi C, Demarest JF, Butini L, Montroni M, Fox CH, Orenstein JM, Kotler DP, Fauci AS. HIV infection is active and progressive in lymphoid tissue during the clinically latent stage of the disease. Nature 1993;362:355-8.